Table 1 Demographic, clinical, laboratory and articular characteristics at start of treatment in PedACR 30 responders and non- responders at month 3, PedACR 70 responders and non-responders at month 12
From: Predictors of response to methotrexate in juvenile idiopathic arthritis
Parameter | PedACR 30 at 3 months (n = 731) | PedACR 70 at 12 months (n = 707) | ||
|---|---|---|---|---|
Responder | Non responder | Responder | Non responder | |
566 (77.4%) | 165 (22.6%) | 466 (65.9%) | 241 (34.1%) | |
Gender, female | 386 (68.2%) | 116 (70.3%) | 318 (68.2%) | 172 (71.4%) |
Systemic onset JIA | 21 (84%) | 4 (16%) | 13 (76.5%) | 4 (23.5%) |
RF-negative polyarthritis | 162 (81%) | 38 (19%) | 135 (70.3%) | 57 (29.7%) |
RF-positive polyarthritis | 18 (81.8%) | 4 (18.2%) | 16 (69.6%) | 7 (30.4%) |
Persistent oligoarthritis | 159 (76.8%) | 48 (23.2%) | 145 (67.4%) | 70 (32.6%) |
Extended oligoarthritis | 71 (73.9%) | 25 (26.1%) | 63 (66.3%) | 32 (33.7%) |
Enthesitis related arthritis | 66 (72.5%) | 25 (27.5%) | 52 (61.9%) | 32 (38.1%) |
Psoriatic arthritis | 55 (76.4%) | 17 (23.6%) | 34 (50.7%)** | 33 (49.3%) |
unclassified JIA | 14 (77.8%) | 4 (22.2%) | 8 (57.1%) | 6 (42.9%) |
Age at onset of disease (years) | 6.8 (3.3-11) | 6.4 (3.8-10.5) | 6.1 (2.9-10.4)** | 8.6 (3.9-12.1) |
Age at MTX start (years) | 9.7 (5.3-13.5) | 9.5 (6–13.3) | 8.5 (4.8-13)*** | 11.4 (6.8-14.5) |
Disease duration before MTX start (years) | 0.9 (0.3-2.9) | 1.1 (0.4-3.2) | 0.6 (0.3-2.3)*** | 1.3 (0.5-3.4) |
Concomitant use of NSAID | 514 (90.8%)** | 149 (90.3%) | 430 (92.3%) | 221 (91.7%) |
Physician’s global assessment of disease activity | 40 (25–65)*** | 29 (19–51.7) | 45 (26–67)*** | 30 (20–55) |
Parent’s global assessment of overall well-being | 44 (19–61)*** | 27 (8–46) | 42 (20–59)** | 31.5 (10–57) |
Parents evaluation of child’s pain | 40 (15–60.2)** | 26.5 (4.2-53) | 40 (17.2-58.7)** | 29.5 (5–56.25) |
CHAQ-DI | 0.5 (0.12-0.87)*** | 0.25 (0–0.6) | 0.5 (0.12-0.9)*** | 0.25 (0–0.75) |
HLA B27 positive | 94 (19.2%) | 35 (22.9%) | 77 (19.4%) | 42 (18.8%) |
ANA positive | 271 (49.2%) | 76 (48.4%) | 240 (53.7%) | 117 (48.9%) |
ESR (mm/h) | 18 (10.0-31)*** | 12 (6.0-23.5) | 19.5 (10–36)*** | 12 (6.5-24) |
CRP (mg/dl) | 4.2 (1.1-12) | 3 (1–7) | 5 (2–15.35)*** | 3 (1–7) |
No. of active joints | 4 (2–8)*** | 2 (1–3) | 4 (2–8)*** | 2 (1–5) |
No of tender joints | 3 (2–7)*** | 2 (1–4 ) | 3 (2–7)** | 2 (1–6) |
No. of swollen joints | 4 (2–8)*** | 2 (1–4) | 3 (2–7)*** | 2 (0–5) |
No. of joints with LOM | 4 (2–8)*** | 2 (1–4) | 4 (2–8)*** | 2 (1–5) |
Presence of morning stiffness | 360 (63.6%)*** | 71 (43%) | 300 (64.4%)*** | 120 (49.8%) |